Clinical trials: Overweight and/or Obesity
Obesity and Overweight
A First-in-human Study of HCR-188 in Overweight or Obese Otherwise Healthy Volunteers Without Type 2 Diabetes
This is a first-in-human study evaluating the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of single and multiple doses of HCR-188 administered as subcutaneous injection(s).
- Trial name
- NCT06845943
- Testing
- HCR-188
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Helicore Biopharma, Inc.
Metabolism and Nutrition Disorder, Overweight or Obesity
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants…
- Trial name
- STEP 1 (NCT03548935)
- Testing
- Semaglutide
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 1,961 people
- Sponsor
- Novo Nordisk A/S
Safety and Tolerability
A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570
The trial is a Phase 1, single-centre, randomised and double-blind within cohorts, placebo-controlled, sequential multiple ascending dose trial including three cohorts in Part 1 in a semi-parallel design and one cohort in Part 2…
- Trial name
- NCT06000891
- Testing
- ZP7570
- Where
- Germany
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Overweight and Obesity
A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE103 or LAE103 in Combination With LAE102 in Healthy Overweight/Obese Participants
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE103 injection in healthy overweight/obese participants or healthy postmenopausal women.
- Trial name
- NCT07230496
- Testing
- LAE103 injection, LAE102 injection in combined with LAE103 injection, Saline
- Where
- 2 sites in Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Laekna Limited
Obesity, Overweight and/or Obesity
A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity
This study looks at how a study medicine called PF-08653944 affects how quickly the stomach empties food after eating. It is being done in adults who are overweight or have obesity.
- Conditions
- Obesity, Overweight and/or Obesity, Overweight, Drug Interaction
- Trial name
- NCT07508241
- Testing
- PF-08653944, Acetaminophen
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Overweight and Obesity
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.
- Trial name
- NCT05051579
- Testing
- LY3502970
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 272 people
- Sponsor
- Eli Lilly and Company
Healthy Participants, Obesity
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or…
- Trial name
- NCT07511205
- Testing
- AZD1043
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity, Overweight and Obesity
A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight
This is a 24 weeks, multicenter, randomized, double-blind, placebo, parallel-controlled Phase IIb trail comparing the efficacy and safety of MDR-001 tablet versus placebo as an adjunct to a reduced calorie diet and increased…
- Trial name
- NCT06606483
- Testing
- MDR-001
- Where
- 19 sites in China
- Volunteers
- 300 people
- Sponsor
- MindRank AI Ltd
Overweight and Obesity
A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide
This is a phase 1, open-label, single-center, randomized, parallel-group trial designed to investigate the pharmacokinetic profiles, safety, and tolerability of a single dose administration of 7.5 mg dapiglutide administered s.c.
- Trial name
- NCT06758583
- Testing
- Dapiglutide 7.5 mg
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zealand Pharma
Overweight and Obesity
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) .
- Trial name
- INLIGHT (NCT06842186)
- Testing
- WVE-007
- Where
- 7 sites in United States, Moldova and 2 more
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Wave Life Sciences USA, Inc.
Overweight, Obesity
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine.
- Conditions
- Overweight, Obesity, Type 2 Diabetes Mellitus
- Trial name
- REDEFINE 2 (NCT05394519)
- Testing
- Cagrilintide, Semaglutide
- Where
- 179 sites in United States, Austria and 11 more
- Volunteers
- 1,200 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity.
- Trial name
- NCT06075667
- Testing
- Tirzepatide
- Where
- 33 sites in United States, Canada and 4 more
- Volunteers
- 160 people
- Sponsor
- Eli Lilly and Company
Overweight or Obesity
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity
This is a randomized, double-blind, single-center, dose-escalation, single ascending dose and multiple ascending dose study of SYH9017 in Chinese participants with overweight and obesity.
- Trial name
- NCT06830343
- Testing
- SYH9017, Wegovy ®
- Where
- China
- Volunteers
- 66 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Obesity
Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects
To evaluate the weight loss effect and safety of 400 mg velneperit and 120 mg orlistat administered individually or combined three times per day for 24 weeks while on a reduced calorie diet (RCD) and also to evaluate the…
- Trial name
- NCT01126970
- Testing
- Velneperit 400 mg, Orlistat 120 mg, Reduced Calorie Diet
- Where
- 25 sites in United States
- Volunteers
- 486 people
- Sponsor
- Shionogi
Overweight, Obesity
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo).
- Trial name
- OASIS 5 (NCT07770841)
- Testing
- Semaglutide
- Where
- 62 sites in United States, Belgium and 8 more
- Volunteers
- 450 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
PH iWell Study to Compare an Online Interactive Technology to Self-directed Care in Overweight or Obese Individuals
This is a six month lifestyle management study to compare the effects of iWell; a dynamic online interactive technology to a self-directed program in overweight or obese individuals.
- Trial name
- NCT01325376
- Testing
- Technology assisted health behavior, Self directed
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- SK Telecom Americas, Inc.
Obesity, Overweight
ORBERA365 Post-Marketing Clinical Follow-up Study
A prospective, multicenter, open-label, post-approval study of the safety and effectiveness of ORBERA36 as a 12-month adjunct to weight reduction for obese adults (BMI ≥ 27 kg/m2 and BMI ≤ 50 kg/m2) or for pre-surgical weight…
- Trial name
- NCT04362774
- Testing
- ORBERA365
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Apollo Endosurgery, Inc.
Obesity, Overweight
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
The aim of this study is to find out how NNC0174-0833 taken with semaglutide works in people who are overweight or obese. Both study medicines have been investigated on their own.
- Trial name
- NCT03600480
- Testing
- NNC0174-0833, Semaglutide
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Novo Nordisk A/S
Breast Ptosis, Obesity
Evaluation of Dermal Closure With an Absorbable Barbed Suture as Compared to a Conventional Absorbable Suture
The objective of this study is to evaluate the use of an absorbable barbed suture as compared to a conventional absorbable suture when used for dermal closure during certain body contouring procedures.
- Trial name
- NCT00959374
- Testing
- V-Loc 180/90 Wound Closure Device, 3-0 Monocryl Absorbable Sutures
- Where
- 8 sites in United States, Germany
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- Medtronic - MITG
Obesity
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.
- Trial name
- CBeyond (NCT06577090)
- Testing
- Nimacimab injection, semaglutide injection, Nimacimab 300 mg injection
- Where
- 16 sites in United States
- Volunteers
- 136 people
- Sponsor
- Skye Bioscience, Inc.